Post-marketing safety concerns with rimegepant based on a pharmacovigilance study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study ; volume:25 ; number:1 ; day:7 ; month:10 ; year:2024 ; pages:1-11 ; date:12.2024
The journal of headache and pain ; 25, Heft 1 (7.10.2024), 1-11, 12.2024
- Klassifikation
-
Soziale Probleme, Sozialdienste, Versicherungen
- Urheber
-
Hu, Jia-Ling
Wu, Jing-Ying
Xu, Shan
Qian, Shi-Yan
Jiang, Cheng
Zheng, Guo-Qing
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s10194-024-01858-4
- URN
-
urn:nbn:de:101:1-2412242105448.395718890546
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hu, Jia-Ling
- Wu, Jing-Ying
- Xu, Shan
- Qian, Shi-Yan
- Jiang, Cheng
- Zheng, Guo-Qing
- SpringerLink (Online service)
Ähnliche Objekte (12)
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?
Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic
Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Big data, medicines safety and pharmacovigilance
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?
Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic
Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Big data, medicines safety and pharmacovigilance
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?
Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic
Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Big data, medicines safety and pharmacovigilance
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data